Cartesian Therapeutics Secures Up to $150M Senior Term Loan, Bolstering Cash Runway
Summary
Cartesian Therapeutics secured a senior secured term loan facility of up to $150 million, led by K2 HealthVentures. An initial $50 million is immediately available, with additional tranches tied to milestones and lender discretion. This significant financing follows recent reports of substantial net losses ($39.2M in Q1 2026) and sharply declining revenue, which had raised concerns about the company's cash runway. The up to $150 million facility substantially extends the company's operational runway and supports its clinical development, mitigating immediate liquidity risks. While primarily non-dilutive, the agreement includes lender conversion rights for up to $15 million of principal at $8.2526 per share, which is a premium to the current stock price.
At the time of this announcement, RNAC was trading at $7.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198.3M. The 52-week trading range was $5.60 to $15.57. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.